Reducing Nonadherence and Rehospitalization through Effective Tardive Dyskinesia Treatment - Live Webinar on September 15, 2026 8PM ET

The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose:

Leslie Citrome, who participated as a planner-reviewer and speaker, has served as a consultant for AbbVie, Acadia, AdhereTech, Altus, Alumis, Axsome, Alkermes, Arc, Auritec, Autobahn, Avant Healthcare Solutions, Biogen, BioXcel, BMS/Karuna, Boehringer Ingelheim, Cadent, Cerevel, Clario/MedAvante/ProPhase, Clinilabs, Compass, Corcept, Definium, Delpor, Eisai, Enteris BioPharma, Health & Wellness Partners, HLS, Idorsia, Inmune Bio, Intra-Cellular, Johnson & Johnson/Janssen, Little Bear, Lundbeck, Luye, Lyndra, MapLight, Marvin, MindMed, Neurelis, Neushen, Neumora, Neurocrine, Noema, Novartis, Noven, Orexo, Otsuka, Ovid, Pontifax/Draig, Praxis, PSL, Real Chemistry, Relmada, Renew Research, Response, Reviva, Sage, Seaport, Sumitomo/Sunovion, Supernus, Teva, and Vanda. He has served as a speaker for AbbVie, Acadia, Alkermes, BMS, Eisai, Idorsia, Intra-Cellular, Johnson & Johnson/Janssen, Lundbeck, Luye, Neopharm, Neurocrine, Noven, Otsuka, Recordati, Takeda, Teva, and Vanda. He holds stock options in Reviva, a public company, and has received royalties or publishing income from Taylor & Francis as Editor-in-Chief of Current Medical Research and Opinion (2022–present), Springer Healthcare for a book, and Elsevier as Topic Editor for Psychiatry in Clinical Therapeutics through spring 2025.

Mark Garofoli, who participated as a planner-reviewer and speaker, has served as a consultant for Tris Pharma, Yaral Pharma, and Kenvue.

April Kraft, who participated as a speaker, has served as a patient ambassador for Neurocrine Biosciences.

These individuals have or have had within the last 24 months financial relationships with one or more ineligible companies. These relationships have been mitigated by PeerPoint Medical Education Institute, AchieveCE and Real World CE.

All other presenters, planners, editors, and staff report no current financial relationships, or financial relationships within the last 24 months, with ineligible companies.

This activity may include discussion of investigational or off-label uses of products or devices. PeerPoint Medical Education Institute and AchieveCE do not endorse or promote the use of any product or device outside its approved indications.

Artificial Intelligence (AI) Disclaimer Statement

Consistent with guidance from the Accreditation Council for Continuing Medical Education (ACCME), any individuals in control of content must disclose if artificial intelligence (AI) was used in the development of this educational activity. Such disclosure should include the name of the AI tool(s) utilized and the extent of its role in content creation.

PeerPoint and AchieveCE reviews all educational materials to ensure they are evidence-based, balanced, and compliant with ACCME Standards for Integrity and Independence, including the identification and mitigation of any potential biases.

AI technologies may be used to support content development; however, they are not a substitute for clinical expertise. Learners are encouraged to apply independent clinical judgment and critically assess the information presented when making decisions related to patient care.